Skip to main content
Nanobiotix logo

Nanobiotix — Investor Relations & Filings

Ticker · NANO ISIN · FR0011341205 LEI · 969500667RSYIH8YL895 PA Manufacturing
Open in API
Filings indexed 793 across all filing types
Latest filing 2019-04-26 Major Shareholding Noti…
Country FR France
Listing PA NANO

About Nanobiotix

https://www.nanobiotix.com/

Nanobiotix is a late-stage clinical biotechnology company pioneering a physics-based approach to cancer treatment through the development of nanotherapeutics. Its lead product candidate, NBTXR3, is a potential first-in-class radioenhancer designed to be injected directly into a tumor. When activated by radiotherapy, NBTXR3 amplifies the radiation dose within the tumor, aiming to destroy cancer cells more effectively without increasing exposure to surrounding healthy tissues. This process is also intended to prime an immune response to target metastatic tumors. The company is developing NBTXR3 for broad application across various solid tumors, with an initial focus on head, neck, and lung cancers through a global licensing agreement with Janssen Pharmaceutica NV.

Recent filings

Filing Released Lang Actions
Franchissement de seuil
Major Shareholding Notification Classification · 99% confidence The document is titled 'Déclaration de franchissement de seuil (article L. 233-7 du code de commerce)' which translates to 'Declaration of crossing a threshold (Article L. 233-7 of the Commercial Code)'. It explicitly states that M. Laurent Lévy crossed the 5% threshold of voting rights in NANOBIOTIX on April 24, 2019, detailing the number of shares and voting rights held. This type of filing, reporting changes in significant share ownership or crossing ownership thresholds, directly corresponds to the definition of Major Shareholding Notification (MRQ). The document is short and specific to this regulatory event.
2019-04-26 French
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document is titled "Information relative au nombre total de droits de vote et d'actions composant le capital social" (Information relative to the total number of voting rights and shares comprising the share capital) and is dated April 25, 2019, referencing data from April 24, 2019. It explicitly cites Article 223-16 of the AMF General Regulation (Autorité des Marchés Financiers, the French financial market regulator). This type of regular disclosure, detailing the total number of shares and voting rights, is a mandatory regulatory filing in France, often related to changes in capital structure or required periodic updates. It is not a full annual report (10-K), an earnings release (ER), or a dividend notice (DIV). It most closely aligns with a specific regulatory disclosure. Since it details the composition of the capital and voting rights, it is a specific type of regulatory announcement. Given the options, it is a mandatory regulatory disclosure that doesn't fit the other specific categories like DIRS, DIV, or SHA (which usually announces a new issue). It is a periodic disclosure of capital structure/voting rights. This fits best under the general 'Regulatory Filings' (RNS) as a specific, non-standard filing, or potentially 'Share Issue/Capital Change' (SHA) if interpreted broadly, but RNS is safer for mandatory periodic regulatory updates not covered elsewhere. However, looking closely at the definitions, this is a specific disclosure about the capital structure and voting rights, which is often required when thresholds are crossed or periodically. Since it is a formal regulatory disclosure about the capital structure, it is a specific regulatory filing. Given the options, and that it is a formal disclosure of voting rights/shares, it is a regulatory filing. If a more specific category existed for 'Total Voting Rights', RNS would be the fallback. I will classify it as RNS as it is a mandatory regulatory filing that doesn't fit the other specific types like DIRS or SHA (which implies an action).
2019-04-25 French
Inside Information / Other news releases
Share Issue/Capital Change Classification · 99% confidence The document is a press release announcing that the CEO, Laurent Levy, exercised founder's warrants (BSPCE) to acquire new shares, resulting in an investment of EUR 960,000 and an upward crossing of the 5% voting rights threshold. This action directly relates to changes in the company's share capital and ownership structure by an insider/executive. This fits the description of 'Director's Dealing' (DIRS) or potentially 'Share Issue/Capital Change' (SHA). However, the primary focus is the transaction by a director/executive and the resulting change in their holding, which strongly aligns with the definition of Director's Dealing (DIRS). Since it involves an executive increasing their stake, DIRS is the most specific fit, although it also involves a capital change (SHA). Given the context of insider transaction reporting, DIRS is preferred over SHA, which usually covers broader capital structure changes or general share issues. It is not an Earnings Release (ER), Interim Report (IR), or Annual Report (10-K). It is a specific announcement about insider share transactions.
2019-04-25 English
Informations privilégiées / Autres communiqués
Share Issue/Capital Change Classification · 99% confidence The document announces that Laurent Levy, the Chairman of the Management Board, has exercised stock warrants (BSPCE) resulting in the acquisition of 160,000 new shares for €960,000. This transaction caused his voting rights to cross the 5% threshold upwards. This event directly relates to insider transactions and changes in significant share ownership by a director/executive. The most specific category is 'Director's Dealing' (DIRS) as it details a director's personal share transaction. While it also involves a change in shareholding (MRQ), the context is explicitly tied to an executive exercising options, making DIRS the primary fit. It is not a general capital change (SHA) or a general regulatory filing (RNS).
2019-04-25 French
Informations privilégiées / Autres communiqués
Share Issue/Capital Change Classification · 99% confidence The document is a press release announcing that NANOBIOTIX has raised 29.5 million Euros through the placement of new ordinary shares via an accelerated book-building process. Key phrases include 'placement d'actions ordinaires nouvelles', 'augmentation de capital', 'produit brut de l'Offre', and details about the share issuance and capital structure change. This clearly indicates a corporate action related to raising capital through issuing new shares, which aligns directly with the definition of 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a dividend notice (DIV). Since it is the announcement of the financing event itself, 'CAP' is the most appropriate classification.
2019-04-09 French
Inside Information / Other news releases
Capital/Financing Update Classification · 98% confidence The document is a press release announcing that NANOBIOTIX raised approximately EUR 29.5 million through the placement of new ordinary shares via an accelerated bookbuild offering. Key phrases include 'NANOBIOTIX RAISES APPROXIMATELY EUR 29.5 MILLION IN PLACEMENT OF ORDINARY NEW SHARES', 'Total gross proceeds from the Offering are expected to be approximately EUR 29.5m', and details about the issue price and the resulting shareholding structure. This clearly describes a corporate financing activity involving the issuance of new capital/shares. This aligns directly with the definition for Capital/Financing Update (CAP). It is not a general earnings release (ER), a full annual report (10-K), or a simple notice of dividend (DIV).
2019-04-09 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.